ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026
Lineage-specific pulmonary transcriptome landscape of coronavirus infection unveils universal immunotherapy for viral pneumonia.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decades, respiratory virus infections have led to millions of cases of critical illness and deaths in humans. However, the high mutation rate of respiratory viruses greatly reduces the effectiveness of virus-target countermeasures such as vaccines and antibodies, necessitating the development of host-target immunotherapies. In a hamster model of SARS-CoV-2 infection, we observed diverse disease outcomes, delineated the variant-specific lung transcriptome landscape, and demonstrated that a rational combination of pharmacological targeting of innate and adaptive immune responses is sufficient to reduce mortality and severe illness caused by Beta, Delta, and EG.1 variants. The synergism of Poly IC-mediated activation of the innate immune response and FK506-mediated inhibition of the adaptive immune response resulted in significant suppression of both viral load and lung injury. Notably, this strategy is also available in humanized mice infected with SARS-CoV-2, H1N1, and H3N2 influenza viruses, suggesting a potent cross-virus broad-spectrum therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.